Loading
PDBj
メニューPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

8PAV

Crystal structure of MST1 with a MAP4K1 SMOL inhibitor

8PAV の概要
エントリーDOI10.2210/pdb8pav/pdb
分子名称Serine/threonine-protein kinase 4 37kDa subunit, 1-[3,5-bis(fluoranyl)-4-[[3-(1,3-thiazol-5-yl)-1~{H}-pyrrolo[2,3-b]pyridin-4-yl]oxy]phenyl]-3-(2-methoxyethyl)urea, GLYCEROL, ... (5 entities in total)
機能のキーワードkinase, inhibitor, drug discovery, transferase
由来する生物種Homo sapiens (human)
タンパク質・核酸の鎖数2
化学式量合計72487.81
構造登録者
Friberg, A. (登録日: 2023-06-08, 公開日: 2024-06-26, 最終更新日: 2025-01-29)
主引用文献Mowat, J.,Carretero, R.,Leder, G.,Aiguabella Font, N.,Neuhaus, R.,Berndt, S.,Gunther, J.,Friberg, A.,Schafer, M.,Briem, H.,Raschke, M.,Miyatake Ondozabal, H.,Buchmann, B.,Boemer, U.,Kreft, B.,Hartung, I.V.,Offringa, R.
Discovery of BAY-405: An Azaindole-Based MAP4K1 Inhibitor for the Enhancement of T-Cell Immunity against Cancer.
J.Med.Chem., 67:17429-17453, 2024
Cited by
PubMed Abstract: Mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1) is a serine/threonine kinase that acts as an immune checkpoint downstream of T-cell receptor stimulation. MAP4K1 activity is enhanced by prostaglandin E2 (PGE2) and transforming growth factor beta (TGFβ), immune modulators commonly present in the tumor microenvironment. Therefore, its pharmacological inhibition is an attractive immuno-oncology concept for inducing therapeutic T-cell responses in cancer patients. Here, we describe the systematic optimization of azaindole-based lead compound , resulting in the discovery of potent and selective MAP4K1 inhibitor (BAY-405) that displays nanomolar potency in biochemical and cellular assays as well as in vivo exposure after oral dosing. BAY-405 enhances T-cell immunity and overcomes the suppressive effect of PGE2 and TGFβ. Treatment of tumor-bearing mice shows T-cell-dependent antitumor efficacy. MAP4K1 inhibition in conjunction with PD-L1 blockade results in a superior antitumor impact, illustrating the complementarity of the single agent treatments.
PubMed: 39331123
DOI: 10.1021/acs.jmedchem.4c01325
主引用文献が同じPDBエントリー
実験手法
X-RAY DIFFRACTION (1.9 Å)
構造検証レポート
Validation report summary of 8pav
検証レポート(詳細版)ダウンロードをダウンロード

246905

件を2025-12-31に公開中

PDB statisticsPDBj update infoContact PDBjnumon